Patient Prostate Cancer Guidelines Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 7
Volume 8
Issue 7

NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.

NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.

Incorporating the clinical experience of the 17 NCCN member institutions, these guidelines offer prostate cancer patients and their families the reliable, specific, and easy-to-understand information they need to make treatment decisions.

In March, the NCCN and ACS released breast cancer guidelines for patients, resulting in 1.5 million visits to the NCCN website.The prostate cancer guidelines are available on the NCCN website (www.nccn.org),and the ACS website (www.cancer.org).

The prostate cancer treatment guidelines for patients will also be published in the August/September 1999 issue of InTouch, PRR, Inc.’s cancer magazine for consumers.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.